FOXO1 content is reduced in cystic fibrosis and increases with IGF-I treatment

International Journal of Molecular Sciences

Volumn 15, Issue 10, 2014, Pages 18000-18022

  Smerieri, Arianna ^a   Montanini, Luisa ^a   Maiuri, Luigi ^b,c   Bernasconi, Sergio ^a   Street, Maria E ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

AKT; Cystic fibrosis related diabetes; ERK1 and 2; FOXO1; IGF I; Insulin; Insulin resistance; IRS1; SOCS2; 2 arrestin

Indexed keywords

BETA ARRESTIN 2; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN HYDROLYSATE; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C; SUPPRESSOR OF CYTOKINE SIGNALING 2; TRANSCRIPTION FACTOR FKHR; TYROSINE; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; INSULIN RECEPTOR SUBSTRATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT PROTEIN; SOCS2 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; EPITHELIUM CELL; FEMALE; GENE SILENCING; IMMUNOPRECIPITATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING; ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SKELETAL MUSCLE;

ADIPOSE TISSUE; ANIMALS; CELL LINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED CFTR; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SKELETAL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84907822242     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151018000     Document Type: Article

References (58)

1. O' Shea, D.; O' Connell, J. Cystic fibrosis related diabetes. Curr. Diabetes Rep. 2014, 14, 511-521.
2. McCormick, J.; Mehta, G.; Olesen, H. V.; Viviani, L.; Macek, M.; Mehta, A.; European Registry Working Group. Comparative demographics of the European cystic fibrois population: A cross-sectional database analysis. Lancet 2010, 375, 1007-1013.
3. Moran, A.; Dunitz, J.; Nathan, B.; Saeed, A.; Holme B.; Thomas W. Cystic fibrosis-related diabetes: Current trends in prevalence, incidence, and mortality. Diabetes Care 2009, 32, 1626-1631.
4. Tofé, S.; Moreno, J. C.; Máiz, L.; Alonso, M.; Escobar, H.; Barrio, R. Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis. Eur. J. Endocrinol. 2005, 152, 241-247.
5. Lanng, S. Glucose intolerance in cystic fibrosis patients. Paediatr. Respir. Rev. 2001, 2, 253-259.
6. Moran, A.; Becker, D.; Casella, S. J.; Gottlieb, P. A.; Kirkman, M. S.; Marshall, B. C.; Slovis, B.; CFRD Consensus Conference Committee. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: A technical review. Diabetes Care 2010, 33, 2677-2683.
7. Lombardo, F.; de Luca, F.; Rosano, M.; Sferlazzas, C.; Lucanto, C.; Arrigo, T.; Messina, M. F.; Crisafulli, G.; Wasniewska, M.; Valenzise, M.; et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur. J. Endocrinol. 2003, 149, 53-59.
8. Street, M. E.; Ziveri, M. A.; Spaggiari, C.; Viani, I.; Volta, C.; Grzincich, G. L.; Virdis, R.; Bernasconi, S. Inflammation is a Modulator of the IGF-IGFBP System Inducing Reduced Bioactivity of IGFs in Cystic Fibrosis. Eur. J. Endocrinol. 2006, 154, 47-52.
9. Street, M. E.; Spaggiari, C.; Ziveri, M. A.; Rossi, M.; Volta, C.; Viani, I.; Grzincich, G. L.; Sartori, C.; Zanzucchi, M.; Raia, V.; et al. Insulin production and resistance in cystic fibrosis: Effect of age, disease activity, and genotype. J. Endocrinol. Investig. 2012, 35, 246-253.
10. Hardin, D. S.; Leblanc, A.; Marshall, G., Seilheimer, D. K. Mechanisms of insulin resistance in cystic fibrosis. Am. J. Physiol. Endocrinol. Metab. 2001, 281, E1022-E1028.
11. Taniguchi, C. M.; Emanuelli, B.; Kahn, R. Critical nodes in signalling pathways: Insights into insulin action. Mol. Cell. Biol. 2006, 7, 85-96.
12. Pessin, J. E.; Saltiel, A. L. Signaling pathways in insulin action: Molecular targets of insulin resistance. J. Clin. Investig. 2000, 106, 165-169.
13. Kitamura, T. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9, 615-623.
14. Shao, S.; Yang, Y.; Yuan, G.; Zhang, M.; Yu, X. Signaling Molecules involved in Lipid-induced pancreatic Beta-Cell Dysfunction. DNA Cell Biol. 2013, 32, 41-49.
15. Marshall, B. C.; Butler, S. M.; Stoddard, M. Epidemiology of cystic fibrosis-related diabetes. J. Pediatr. 2005, 146, 681-687.
16. Luciani, A.; Vilella, V. R.; Esposito, S.; Brunetti-Pierri, N.; Medina, D.; Settembre, C.; Gavina, M.; Pulze, L.; Giardino, I.; Pettoello-Mantovani, M.; et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat. Cell. Biol. 2010, 12, 863-875.
17. Kim, M. K.; Kim, H. S.; Lee, I. K.; Park, K. G. Endoplasmic reticulum stress and insulin biosynthesis: A review. Exp. Diabetes Res. 2012, 509437.
18. Li, Q.; Verma, I. M. NFkB regulation in the immune system. Nat. Rev. Immunol. 2002, 2, 725-734.
19. Berger, M. Inflammatory mediators in cystic fibrosis lung disease. Allergy Asthma Proc. 2002, 23, 19-25.
20. Aguirre, V.; Werner, E. D.; Giraud, J.; Lee, Y. H.; Shoelson, S. E.; White, M. F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 2002, 277, 1531-1537.
21. Ozes, O. N.; Akca, H.; Mayo, L. D.; Gustin, J. A.; Maehama, T.; Dixon, J. E.; Donner, D. B. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signalling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. USA 2001, 98, 4640-4645.
22. Senn, J. J.; Klover, P. J.; Nowak, I. A.; Mooney, R. A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51, 3391-3399.
23. Mooney, R. A.; Senn, J.; Cameron, S.; Inamdar, N.; Boivin, L. M.; Shang, Y.; Furlanetto, R. W. Suppressors of cytokine signaling-1 and-6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J. Biol. Chem. 2001, 276, 25889-25893.
24. Zadjali, F.; Santana-Farre, R.; Vesterlund, M.; Carow, B.; Mirecki-Garrido, M.; Hernandez-Hernandez, I.; Flodström-Tullberg, M.; Parini, P.; Rottenberg, M.; Norstedt, G.; et al. SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice. FASEB J. 2012, 26, 3282-3291.
25. Feng, X.; Wang, W.; Liu, J.; Liu, Y. β-Arrestins: Multifunctional signalling adaptors in type 2 diabetes. Mol. Biol. Rep. 2011, 38, 2517-2528.
26. DeWire, S. M.; Ahn, S.; Lefkowitz, R. J.; Shenoy, S. K. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 2007, 69, 483-510.
27. Manson, M. E.; Corey, D. A.; White, N. M.; Kelley, T. J. cAMP-mediated regulation of cholesterol accumulation in cystic fibrosis and Niemann-Pick type C cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295, L809-L819.
28. DeFronzo, R. A.; Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32, S157-S163.
29. Silveira, L. R.; Fiamoncini, J.; Hirabara, S. M.; Procópio, J.; Cambiaghi, T. D.; Pinheiro, C. H.; Lopes, L. R.; Curi, R. Updating the effects of fatty acids on skeletal muscle. J. Cell. Physiol. 2008, 217, 1-12.
30. McDonald, A.; Williams, R. M.; Regan, F. M.; Semple, R. K.; Dunger, D. B. IGF-I treatment of insulin resistance. Eur. J. Endocrinol. 2007, 157, 51-56.
31. Savage, M. O.; Camacho-Hübner, C.; Dunger, D. B. Therapeutic applications of the insulin-like growth factors. Growth Horm. IGF Res. 2004, 14, 301-308.
32. Street, M. E.; Viani, I.; Ziveri, M. A.; Volta, C.; Smerieri, A.; Bernasconi, S. Impairment of insulin receptor signal transduction in placentas of intra-uterine growth-restricted newborns and its relationship with fetal growth. Eur. J. Endocrinol. 2011, 164, 45-52.
33. Lu, M.; Wan, M.; Leavens, K. F.; Chu, Q.; Monks, B. R.; Fernandez, S.; Ahima, R. S.; Ueki, K.; Kahn, C. R.; Birnbaum, M. J. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 2012, 18, 388-396.
34. Van der Vos, K. E.; Coffer, P. J. FOXO-binding partners: It takes two to tango. Oncogene 2008, 27, 2289-2299.
35. Hardin, D. S.; Ahn, C.; Rice, J.; Rice, M.; Rosenblatt, R. Elevated gluconeogenesis and lack of suppression by insulin contribute to cystic fibrosis-related diabetes. J. Investig. Med. 2008, 56, 567-573.
36. Zhang, K.; Li, L.; Qi, Y.; Zhu, X.; Gan, B.; DePinho, R. A.; Averitt, T.; Guo, S. Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology 2012, 153, 631-646.
37. Hardin, D. S.; LeBlanc, A.; Para, L.; Seilheimer, D. K. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes 1999, 48, 1082-1087.
38. Gentzsch, M.; Choudry, A.; Chang, X.; Pagano, R. E.; Riordan, J. R. Misassembled mutant ΛF508 CFTR in the distal secretory pathway alters cellular lipid trafficking. J. Cell. Sci. 2007, 120, 447-455.
39. Yang, X.; Zhou, G.; Ren, T.; Li, H.; Zhang, Y.; Yin, D.; Qian, H.; Li, Q. β-arrestin prevents cell apoptosis through pro-apoptotic ERK1/2 and p38 MAPKs and anti-apoptotic Akt pathways. Apoptosis 2012, 17, 1019-1026.
40. Bost, F.; Aouadi, M.; Caron, L.; Even, P.; Belmonte, N.; Prot, M.; Dani, C.; Hofman, P.; Pagès, G.; Pouysségur, J.; et al. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 2005, 54, 402-411.
41. Martel, G.; Rousseau, S. TPL2 signalling: From Toll-like receptors-mediated ERK1/ERK2 activation to Cystic Fibrosis lung disease. Int. J. Biochem. Cell Biol. 2014, 52, 146-151.
42. Mohan, K.; Miller, H.; Dyce, P.; Grainger, R.; Hughes, R.; Vora J.; Ledson, M.; Walshaw, M. Mechanisms of glucose intolerance in cystic fibrosis. Diabet. Med. 2009, 26, 582-588.
43. Gupta, D.; Leahy, A. A.; Mongan, N.; Peshavaria, M.; Jetton, T. L.; Leahy, J. L. Peroxisome proliferator-activated receptor γ (PPARγ) and its target genes are downstream effectors of FoxO1 protein in islet β-cells: Mechanism of β-cell compensation and failure. J. Biol. Chem. 2013, 288, 25440-25449.
44. Martinez, S. C.; Tanabe, K.; Cras-Meneur, C.; Abumrad, N. A.; Bernal-Mizrachi, E.; Permutt, M. A. Inhibition of FOXO1 protects pancreatic islet beta-cells against fatty acid and endoplasmic reticulum stress-induced apoptosis. Diabetes 2008, 57, 846-859.
45. Miyazaki, S.; Minamida, R.; Furuyama, T.; Tashiro, F.; Yamato, E.; Inagaki, S.; Miyazaki, J. Analysis of FOXO1-regulated genes using FOXO1-deficient pancreatic beta cells. Genes Cell 2012, 17, 758-767.
46. Lee, H. W.; Cheng J.; Kovbasnjuk, O.; Donowitz, M.; Guggino, W. B. Insulin-like growth factor 1 (IGF-1) enhances the protein expression of CFTR. PLoS One 2013, 8, e59992.
47. Yuen, K.; Frystyk, J.; Umpleby, M.; Fryklund, L.; Dunger, D. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults. J. Clin. Endocrinol. Metab. 2004, 89, 3956-3964.
48. Simpson, H. L.; Jackson, N. C.; Shojaee-Moradie, F.; Jones, R. H.; Russell-Jones, D. L.; Sonksen, P. H.; Dunger, D. B.; Umpleby, A. M. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type I diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 425-432.
49. Bucuvalas, J. C.; Chernausek, S. D.; Alfaro, M. P.; Krug, S. H.; Ritschel, W.; Wilmot, R. W. Effect of insulin-like growth factor-I treatment in children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2001, 33, 576-581.
50. Schnabel, D.; Grasemann, C.; Staab D.; Wollmann, H.; Ratjen, F. A multicenter, randomized, double-blind, placebocontrolled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 2007, 119, e1230-e1238.
51. Thaker, V.; Haagensen, A. I.; Carter, B.; Fedorowicz, Z.; Houston, B. W. Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database Syst. Rev. 2013, 6, CD008901.
52. Gruenert, D. C.; Basbaum, C. B.; Welsh, M. J.; Li, M.; Finkbeiner, W. E.; Nadel, J. A. Characterization of human tracheal epithelial cells transformed by an origin-defective simian virus 40. Proc. Natl. Acad. Sci. USA 1988, 85, 5951-5955.
53. Ehrhardt, C.; Collnot, E. M.; Baldes, C.; Becker, U.; Laue, M.; Kim, K. J.; Lehr, C. M. Towards an in vitro model of cystic fibrosis small airway epithelium: Characterisation of the human bronchial epithelial cell line CFBE41o-. Cell Tissue Res. 2006, 323, 405-415.
54. Street, M. E.; Miraki-Moud, F.; Sanderson, I. R.; Savage, M. O.; Giovannelli, G.; Bernasconi, S.; Camacho-Hübner, C. Interleukin-1β (IL1β) and IL6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells. J. Endocrinol. 2003, 179, 405-415.
55. Perez, A.; Issler, A. C.; Cotton, C. U.; Kelley, T. J.; Verkman, A. S.; Davis, P. B. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292, L383-L395.
56. Muanprasat, C.; Sonawane, N. D.; Salinas, D.; Taddei, A.; Galietta, L. J.; Verkman, A. S. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: Mechanism, structure-activity analysis, and in vivo efficacy. J. Gen. Physiol. 2004, 124, 125-137.
57. Van Doorninck, J. H.; French, P. J.; Verbeek, E.; Peters, R. H.; Morreau, H.; Bijman, J.; Scholte, B. J. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J. 1995, 14, 4403-4411.
58. Nicklas, W.; Baneux, P.; Boot, R.; Decelle, T.; Deeny, A. A.; Fumanelli, M.; Illgen-Wilcke, B.; FELASA (Federation of European Laboratory Animal Science Associations Working Group on Health Monitoring of Rodent and Rabbit Colonies). Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab. Anim. 2002, 36, 20-42.